Journal of Cardiac Failure
Volume 16, Issue 2 , Pages 121-127 , February 2010

Long-Term Outcomes With Ambrisentan Monotherapy in Pulmonary Arterial Hypertension

  • Shannon E. Blalock

      Affiliations

    • Childrens Medical Center Dallas
    • Corresponding Author InformationReprint requests: Shannon Blalock, 1935 Medical Center Drive, Division of Cardiology, 3rd Floor, Dallas, TX 75235. Phone: (214) 456-6333; Fax: (214) 456-6154.
    • ,
  • Susan Matulevicius

      Affiliations

    • Parkland Hospital/UT Southwestern University Hospital, University of Texas Southwestern Medical Center at Dallas
    • ,
  • Laura C. Mitchell

      Affiliations

    • Parkland Hospital/UT Southwestern University Hospital, University of Texas Southwestern Medical Center at Dallas
    • ,
  • Sharon Reimold

      Affiliations

    • Parkland Hospital/UT Southwestern University Hospital, University of Texas Southwestern Medical Center at Dallas
    • ,
  • John Warner

      Affiliations

    • Parkland Hospital/UT Southwestern University Hospital, University of Texas Southwestern Medical Center at Dallas
    • ,
  • Ronald Peshock

      Affiliations

    • Parkland Hospital/UT Southwestern University Hospital, University of Texas Southwestern Medical Center at Dallas
    • ,
  • Fernando Torres

      Affiliations

    • Parkland Hospital/UT Southwestern University Hospital, University of Texas Southwestern Medical Center at Dallas
    • ,
  • Kelly M. Chin

      Affiliations

    • Parkland Hospital/UT Southwestern University Hospital, University of Texas Southwestern Medical Center at Dallas

Received 3 June 2009 ,Revised 30 August 2009 ,Accepted 29 September 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by Grant Number UL1RR024982 and KL2RR024983, titled, “North and Central Texas Clinical and Translational Science Initiative” (Milton Packer, MD, PI) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research, and its contents are solely the responsibility of the authors and do not necessarily represent the official view of the NCRR or NIH. Information on NCRR is available at http://www.ncrr.nih.gov/. Information on Re-engineering the Clinical Research Enterprise can be obtained from http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp.

 Dr. Torres has served as a speaker/consultant and has received research grants from Gilead, which makes ambrisentan. Dr. Chin has received research grants from Gilead and has served as a speaker/consultant for Actelion and United Therapeutics.

PII: S1071-9164(09)01092-6

doi: 10.1016/j.cardfail.2009.09.008

Journal of Cardiac Failure
Volume 16, Issue 2 , Pages 121-127 , February 2010

Article Tools

* Image Usage & Resolution